Roderick de Greef

Chairman of the Board

Mr. de Greef has served as the Chairman of our Board of Directors since November 2008. Mr. de Greef is the principal of Taveyanne Capital Advisors, Inc., a corporate firm providing corporate finance consulting services. Mr. de Greef served as the Chief Financial Officer of Cambridge Heart from October 2005 to July 2007. Prior to that, Mr. de Greef served as the Executive Vice President, Chief Financial Officer and Secretary of Cardiac Science, Inc. from March 2001 to September 2005 when the company merged with Quinton Cardiology, Inc. From 1995 to 2001, Mr. de Greef provided corporate finance advisory services to a number of early stage companies including Cardiac Science, where he was instrumental in securing equity capital beginning in 1997, and advising on merger and acquisition activity. Mr. de Greef has a B.A. in Economics and International Relations from San Francisco State University and an M.B.A. from the University of Oregon. Mr. de Greef serves on the boards of three other publicly traded companies including Endologix, Inc., based in Irvine, CA, BioLife Solutions, Inc., located in Bothell, WA, and Elephant Talk Communications, Inc., headquartered in Amsterdam, The Netherlands.

Ali Haghighi-Mood, PhD

President and Chief Executive Officer

Dr. Ali Haghighi-Mood is Chief Executive Officer. He joined Cambridge Heart in January 1997 as a research scientist coming from an academic background. From 2000 to 2008 he served in various management positions within the company including Chief Technology Officer and Chief Operating Officer. During his tenure at Cambridge Heart, Dr. Haghighi-Mood has been a driving force behind the company’s research and development efforts. He is the inventor of a number of US and European patents including the company’s proprietary technology, the Analytic Spectral Method for the Measurement of T-Wave Alternans. Dr. Haghighi-Mood holds BS and MS degrees in Electrical Engineering from the University of Tehran and a PhD degree in Biomedical Engineering from the University of Sussex, UK.

Paul J. McCormick

Executive Chairman, Cardiogenesis, Inc.

Paul McCormick was elected to our Board of Directors in December 30th, 2009. Mr. McCormick served as Executive Chairman of Cardiogenesis, Inc., a manufacturer of cardiovascular laser systems and disposables from June 2009 until the sale of the company in May 2011. From January 1998 to May 2010, Mr. McCormick served in various corporate capacities at Endologix Inc., a developer and manufacturer of minimally invasive treatments for vascular diseases, including Vice President of Sales and Marketing, President and Chief Operating Officer, President and Chief Executive Officer, and as Corporate Director. Currently Mr. McCormick is a director at Cianna Medical, a privately-held medical device company. Mr. McCormick has more than 30 years of experience in the medical device industry. Prior to 1998, Mr. McCormick held various sales and marketing positions at Progressive Angioplasty Systems, Heart Technology, Trimedyne Inc., and U.S. Surgical Corporation. Mr. McCormick holds a B.S. in Arts-Economics from Northwestern University Evanston and an Executive Sales and Marketing certification from Columbia University.

John F. McGuire

Former President and CEO, American Red Cross

Prior to joining the American Red Cross, Mr. McGuire was President of Whatman, PLC Filtration Products, an international leader in separations technology and provider of materials and devices to laboratory and healthcare markets. During his tenure at Whatman, Mr. McGuire successfully restructured the Company to maximize its growth and profitability. In addition, Mr. McGuire has held prominent positions for over 22 years in the field of biomedical technology and the blood banking industry.

Jeffrey Wiggins

Former Principal of Dresdner RCM Capital Management

Mr. Wiggins was elected to our Board of Directors on May 31st, 2008. Mr. Wiggins is a former Principal of Dresdner RCM Capital Management, where he was responsible for in excess of $4 billion dollars in health care related investments. Having joined Dresdner RCM in 1993, he became a Principal in 1997. While there, he started and managed several portfolios, advised other managers in their health care holdings, and initiated two public mutual funds. Prior to that time at O’Connor & Associates, Mr. Wiggins managed a derivative-based hedge fund portfolio investing in biotechnology, medical technology, pharmaceuticals, and health care services.